Leptin as a predictor of cardiovascular disease: A cross-sectional study in a sample of Jordanian patients


ABSTRACT

Objective: To investigate whether elevated serum leptin levels correlate positively with the occurrence of cardiovascular disease in the randomly selected sample of patients.

Methods: The study enrolled 630 subjects, 322 females and 308 males, who were randomly selected among patients attending the outpatient clinic of Endocrinology and Diabetes in King Hussein Medical Center, Royal Medical Services, Jordan. Diabetes was diagnosed according to American Diabetes Association (ADA) criteria, and blood samples were analyzed using standard biochemical kits at KHMC laboratory. The Data collected were later analysed using SPSS IBM software and Receiver Operating Characteristic Curves were used to determine the positive correlation of elevated serum leptin levels among individuals suffering from cardiovascular disease.

Results: This study revealed a positive relation between the occurrence of cardiovascular disease and serum leptin levels, with the strongest association being observed among males, with an area under the curve (AUC) of 0.734 as compared to AUC of 0.658 for the female group and 0.588 for both genders together. Significant difference was also observed between diabetic and non-diabetic individuals of both genders, with mean serum leptin levels of 20.19±13.47 and 16.10±15.98 respectively.

Conclusion: Our results confirm that serum leptin levels are higher in patients with clinically evident CVD, however further data are needed to justify it’s clinical use as a predictor of CVD. Acknowledgement of the limitations of this study may aid in future attempts to demonstrate this relation through conducting similar studies aiming to shed light on this interesting relation which will help us understand with further detail the pathophysiology of obesity-related cardiovascular disease.

Key words: Cardiovascular disease, Diabetes mellitus, Obesity, Serum Leptin levels.
2016 are overweight, 13% of whom are classified as obese. This increase is mainly attributed to the globalization-urbanization phenomenon. (2) Leptin is a 16 kDa hormone, encoded by the obese gene (ob). It is a peptide hormone formed of 165 amino acids. Identified almost 20 years ago, leptin has since then attracted a lot of attention from researchers in the field of energy utilization and weight control. (3-5) Leptin receptor is a transmembrane protein structurally homologous to gp130 receptor family. Binding of leptin to its receptor results in homodimerization and activation of intracellular messengers such as STAT (signal transducer and activator transcription factor), Mitogen-Activated Protein (MAP) and Nitrous Oxide (NO) and others. Leptin is mainly secreted by adipocytes, hence its level in the serum is directly proportional to the amount of adipose tissue present in the subject. It mainly targets receptors in the hypothalamus, through which it ensures maintaining stable energy stores within a relatively narrow range - thus when fat mass increases, leptin levels increase too, suppressing appetite inducing weight loss, and vice versa. It has been shown to increase overall sympathetic activity, facilitate glucose metabolism and improve insulin sensitivity. (5,6) Interestingly, though, obese individuals are leptin resistant rather than deficient, meaning they would need larger amounts of this hormone to achieve favourable results and achieve balance. (7) Although leptin in the normal physiological range has a protective role in regulating pressure and volume in human body, this hormone may have deleterious effects if present in excess, possibly acting as an independent risk factor for the development of cardiovascular disease. (6,8) The prevalence of obesity in northern Jordan according to Khader et al was estimated to be 28.1% among males and 53.1% among females, (9) which reflects the huge impact these figures may have on the health care system. According to WHO the leading cause of mortality in Jordan in 2014 was cardiovascular disease- estimated to be 35% of the overall mortality. (10) Hence it is of great importance to identify possible risk factors that may be implemented in obesity related cardiovascular disease. The aim of this study, therefore, is to investigate whether elevated serum leptin levels correlate positively with the occurrence of cardiovascular disease. Methods and materials

Subjects:
This cross-sectional study was conducted in the endocrinology clinic at King Hussein Medical City in Amman, Jordan, during the period from August 2009 to May 2010. 630 subjects were enrolled (322 females and 308 males), all aged between 20-70 years. The subjects were randomly selected among visitors of the endocrine clinic at the KHMC during the previously stated period (from August 2009 to May 2010), and every other visitor to the morning clinics was recruited unless proven unfit due to exclusion criteria. Exclusion criteria: Individuals with T1DM were excluded, as well as pregnant females and anyone falling outside the age-range. Also individuals with chronic kidney disease or hypogonadism were excluded. The study was approved by the Royal Medical Services Ethics Committee, and informed consent was obtained from each subject enrolled. Demographic and health history data collection was done by Dr Ahmad Obaidat (see authors) and a specialized team of nutritionists through revision of individuals’ health records and filling forms with relevant data.

Methods
Anthropometric measures were recorded following standard procedures. (11,12) Blood samples were collected after a 10-12 hour overnight fast. Standard biochemical kits (Cobas c 311 Hitachi) were used to run the tests following standard procedures at Princess Iman Centre for Laboratory Research and Science Center, KHMC. Body mass index was calculated using the formula BMI = weight (kg)/Height² (m²). Subjects were classified to non-obese: BMI 18.5-24.9, overweight 25.0-27.5, and obese 27.5-40 kg/m². Diabetes was diagnosed according to American Diabetes Association (ADA) recommendations as fasting plasma glucose 126mg/dl on two or more occasions and/or HbA1c 6.5%. Subject’s medical records were used to identify patients with composite
cardiovascular disease and ischemic heart disease, including individuals with previous acute coronary event, chronic stable angina, patients with previous coronary artery bypass surgery of following coronary angiography with proved coronary artery disease (occlusive or non-occlusive).

**Statistical analysis:**
Data were analyzed using the statistical package for social sciences IBM SPSS Statistics 20. Data were presented in terms of mean ± standard deviation, p values were provided where indicated. Levels of statistical significance were identified as p values of ≤ 0.05, ≤ 0.01 and ≤ 0.001. Receiver operating characteristic curves (ROC) were used to determine the efficiency of leptin as a biochemical marker for cardiovascular disease (CVD).

**Results**
Descriptive: demographic analysis of the study group (Table I): Anthropometric and clinical indices are shown including means and standard errors of deviation for each variable. 630 individuals were recruited, 322 (51%) women and 308 (49%) men. The mean age for the study group was 43.27±0.5 years with no significant difference between males and females. The mean BMI was 30.40 ± 0.36 for males, and 32.24 ± 0.47 for females. 105 (34.1%) of men and 187 (57.6%) of women were hypertensive. 133 (43.2%) of men and 134 (41.6%) of women had diabetes mellitus, and 180 (58.4%) of men, 136 (42.2%) of women were hyperlipidemic. Clinical and biochemical indices by gender for the study group. (Table II): Clinical and biochemical indices are displayed showing means and standard errors of deviation for each variable. The mean fasting blood glucose was 124.30 ±3.39 for males, and 119. 15 ± 3.25 for females with no statistically significant difference. The mean leptin in the male study group was 10.64 ± 9.94 and in the females 23.96 ± 9.94 (p-value < 0.001). Receiver operating characteristic curves (ROC) were used to determine the efficiency of leptin as a biochemical marker for cardiovascular disease (CVD).
Figure 1 (leptin levels compared to gender, obesity and diabetes)

Figure 2 (leptin levels in obese diabetic, obese non-diabetic

Figure 3 Area Under the Curve for both genders with CVD: 0.588

Figure 4 Area Under the Curve for females with CVD: 0.658

Figure 5 Area Under the Curve for males with CVD: 0.734

JOURNAL OF THE ROYAL MEDICAL SERVICES
Vol. 24 No.3 Dec 2017 37
Table I: Anthropometric Characteristics by gender for the study group

<table>
<thead>
<tr>
<th>Indices</th>
<th>Mean± Standard Error of Deviation</th>
<th>Total (n=630)</th>
<th>Men (n= 308)</th>
<th>Women (n=322)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>43.26±0.54</td>
<td>42.19 ± 0.75</td>
<td>44.28 ±0.79</td>
<td></td>
</tr>
<tr>
<td>Weight( Kg)</td>
<td>85.82±1.12</td>
<td>90.34 ± 1.16</td>
<td>81.30 ± 1.21</td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>165.53±0.35</td>
<td>172.18 ± 0.35</td>
<td>158.89 ± 0.35</td>
<td></td>
</tr>
<tr>
<td>Waist Circumference (cm)</td>
<td>99.73±0.7</td>
<td>101.79 ± 0.83</td>
<td>97.76 ± 1.09 P &lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index (Kg/ m²)</td>
<td>31.79±0.38</td>
<td>30.40 ± 0.36</td>
<td>32.24 ± 0.47</td>
<td></td>
</tr>
<tr>
<td>Waist to Height Ratio</td>
<td>0.605±0.01</td>
<td>0.59 ± 0.00</td>
<td>0.62 ± 0.01</td>
<td></td>
</tr>
</tbody>
</table>

Table II: Clinical and Biochemical Indices By gender

<table>
<thead>
<tr>
<th>Indices</th>
<th>Mean ± Standard of Error of Mean</th>
<th>Total (n=630)</th>
<th>Men (n=308)</th>
<th>Women (n=322)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Blood Glucose (mg/dl)</td>
<td>121.67±2.35</td>
<td>124.30± 3.39</td>
<td>119.15 ± 3.25</td>
<td></td>
</tr>
<tr>
<td>Systolic Blood Pressure (mmHg)</td>
<td>134.87±1.12</td>
<td>132.69 ± 1.73</td>
<td>136.96 ± 1.42</td>
<td></td>
</tr>
<tr>
<td>Diastolic Blood Pressure (mmHg)</td>
<td>81.74±0.46</td>
<td>79.58 ± 0.68</td>
<td>83.80 ± 0.61 p&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Leptin Level (nm/ml)</td>
<td>10.80±0.43</td>
<td>10.63 ± 9.94</td>
<td>23.96 ± 6.6 P &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>High Density Lipoprotein (mg/dl)</td>
<td>48.44±0.78</td>
<td>46.23 ± 0.75</td>
<td>50.66± 0.83 p &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>163.18±4.72</td>
<td>172.45 ± 4.47</td>
<td>153.91 ± 4.96 P &lt; 0.01</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6 : (leptin levels compared to insulin secretion)
Discussion
This is one of a few studies conducted to investigate whether elevated serum leptin levels correlate positively with the occurrence of cardiovascular disease in the randomly selected sample of patients. The link between leptin and cardiovascular disease could be, in part, due to the fact that leptin is a peptide hormone primarily synthesized by adipocytes, thus its level is directly proportional to the amount of adipose tissue in the individual. As is well recognized, obesity is a worldwide rapidly growing metabolic disorder with dramatic burden on the health and economy of both the developed and developing countries. Long term studies relate obesity to cardiovascular disease; some even prove it to be an independent risk factor for coronary atherosclerosis. This occurs mostly secondary to activation of the sympathetic nervous system, as well as impairment of the endothelial function.

Though leptin deficiency is the cause of obesity for some rare cases, most obese individuals are leptin resistant, thus having high levels of leptin in their circulation. Our results are in keeping with this observation, as leptin levels were consistently higher among obese individuals as opposed to non-obese subjects, and this was demonstrated in both genders with a statistically significant p-value of < 0.001. Leptin levels were also higher in females, and this is mostly due to the lowering effect testosterone exerts on leptin production. Leptin has also been identified in several studies as an independent biomarker for metabolic syndrome. In the Framingham Third Generation Cohort, leptin concentrations were associated with increased risk of metabolic syndrome. This effect may be through activation of lipolytic hormones, such as glucocorticoids and catecholamines, leading to hyperlipidemia, central obesity and insulin resistance. Metabolic syndrome itself is a constellation of metabolic disorders that increase the risk of CVD. Upon further analysis, our results have shown a statistically significant difference in leptin levels among patients with diabetes mellitus compared to patients with normal glucose metabolism. This is consistent with data from several different populations all in keeping with a positive correlation between insulin level and leptin concentration. As insulin resistant men showed higher levels of leptin than insulin sensitive men regardless of the body fat mass (Figure 6). The possible explanation for this observation may be due to leptin activity in the pancreas, which would normally inhibit insulin secretion, however due to insulin resistance there is loss of leptin-induced inhibition of glucose-stimulated insulin secretion, which contributes to insulin resistance and Type 2 Diabetes. But how would leptin act at the molecular level as an independent risk factor for CVD? In it’s normal physiological levels leptin plays a key role in blood pressure and volume regulation, as it is capable of regulating cardiac and vascular contractility through a local NO – dependent mechanism. So in vascular endothelial cells leptin activates the stress-activated protein kinase (SAPK) and Jun NH2-terminal kinase (JNK)transduction pathways, which are also activated by ROS – thus explaining the hazardous effects of sustained hyperleptinemia. However in the case of hyperleptinaemia due to leptin resistance, it has been considered as a pathophysiological trigger for cardiovascular disease, accounted even as an independent risk factor. Once leptin signalling in the hypothalamus is disrupted, the energy balance loses equilibrium and obesity ensues. Given the fact that leptin resistance is tissue specific, it tends to affect the hypothalamic signalling only, whereas the peripheral signalling remains unchanged. For instance the sympathetic activation to maintain blood pressure control is still retained, partly attributing to the deleterious effects of leptin when present in high levels. When APOE deficient mice were treated with recombinant leptin treatment, it further promoted atherosclerosis and thrombosis. On the other hand, leptin resistance is also proatherogenic. Once leptin binds to its receptor, IRS-1 and IRS-2 activity increases, which eventually leads to suppressed PI-3 activity, a well known positive inotropic mediator for the heart and the vasculature, which leads to reduced cardiac inotropicity. This may also explain the onset of insulin resistance observed in patients.
with chronic hyperleptinemia. An interesting observation, though, is that Leptin may also play an important role in the catabolic cardiac cachexia which affects patients with congestive heart failure—as it has been found to be elevated in individuals with congestive heart failure. Our results have shown a positive relation between serum leptin levels and the existence of clinically evident cardiovascular disease. The findings were more consistent among males, as the AUC (Area Under the Curve) for leptin used as a risk factor for CVD was 0.734 (figure 5), and in females 0.658 (Figure 4), revealing a less positive correlation. These findings are consistent with several studies that have been conducted attempting to demonstrate the relation between leptin and CVD. Li et al (21) demonstrated that serum leptin levels are positively correlated with CVD and Metabolic Syndrome in a group of 957 Taiwanese adults. Wallace et al (28) in a large prospective study (WOSCOPS) demonstrated that leptin is a novel, independent risk factor for CVD. Preliminary data from the group included in the study linked leptin to C-Reactive Protein (CRP)—a marker of chronic low grade inflammation and predictor of risk for CVD. Welch et al demonstrated the positive correlation between diabetes and hyperleptinemia in a group of 5804 patients both males and females, studied over the period between 197-1999. However the data provided weren’t sufficient to demonstrate a positive correlation between hyperleptinemia and cardiovascular disease. Their findings were also consistent with the Quebec cardiovascular study (40).

**Conclusion**

In conclusion, our results confirm that leptin levels are higher in patients with clinically evident CVD, however further data are needed to justify it’s clinical use as a risk factor for CVD. Acknowledgement of the limitations of this study may aid in future attempts to demonstrate this relation through conducting similar studies aiming to shed light on this interesting relation which will help us understand with further detail the risk factors implemented in obesity-related cardiovascular disease.

**Study limitations:**

Single measurements of leptin levels may not be a fair reflection of the mean levels of leptin in the individuals involved in the study group (leptin variability). Additionally the degree of diabetes control was not accounted for when measuring leptin levels, as well as other factors that might interfere with metabolism such as thyroid dysfunction. The cardiovascular disease in this study was identified as only the clinically evident cardiovascular disease—which may not be sufficient to account for the true existence of cardiovascular disease among these individuals given the fact that some patients may harbour silent atherosclerosis. A possible alternative might be the usage of cardiovascular risk profiles or software calculators that predict the risk of CVD.

**References**


